Gimv(GIMB)株式概要ギムヴNVは、直接投資とファンド・オブ・ファンズ投資を専門とするプライベート・エクイティおよびベンチャー・キャピタル会社である。 詳細GIMB ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長0/6過去の実績2/6財務の健全性4/6配当金2/6報酬当社が推定した公正価値より48.2%で取引されている 過去5年間の収益は年間11.5%増加しました。 リスク分析高いレベルの非現金収入 4.36%の配当はフリーキャッシュフローで十分にカバーされていない すべてのリスクチェックを見るGIMB Community Fair Values Create NarrativeSee what 16 others think this stock is worth. Follow their fair value or set your own to get alerts.NEW485,257 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG485,257 investors already sharing narrativesYour Fair Value€Current Price€44.7531.7% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-49m351m2016201920222025202620282031Revenue €350.6mEarnings €268.2mAdvancedSet Fair ValueView all narrativesGimv NV 競合他社BrederodeSymbol: ENXTBR:BREBMarket cap: €3.0bTINCSymbol: ENXTBR:TINCMarket cap: €545.9mWhitestone GroupSymbol: ENXTBR:ROCKMarket cap: €121.5miFASTSymbol: SGX:AIYMarket cap: S$2.9b価格と性能株価の高値、安値、推移の概要Gimv過去の株価現在の株価€44.7552週高値€50.1052週安値€41.80ベータ0.521ヶ月の変化-0.78%3ヶ月変化-9.23%1年変化5.54%3年間の変化7.19%5年間の変化-16.67%IPOからの変化-13.40%最新ニュースお知らせ • Jul 02Impact Healthcare SA acquired an unknown majority stake in Les Psy Réunis SA from Gimv NV (ENXTBR:GIMB).Impact Healthcare SA acquired an unknown majority stake in Les Psy Réunis SA from Gimv NV (ENXTBR:GIMB) on June 30, 2026. Elizabeth and Andrei Cicotti will rollover of their existing stake. Christoph Neeracher, Thomas Rohde, Susanne Schreiber and Martin Leu of Bär & Karrer Ltd. acted as legal advisors for Gimv NV. Stout advised Elizabeth and Andrei Cicotti. Impact Healthcare SA completed the acquisition of an unknown majority stake in Les Psy Réunis SA from Gimv NV (ENXTBR:GIMB) on June 30, 2026.Board Change • Jun 22Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 9 experienced directors. 2 highly experienced directors. 5 independent directors (6 non-independent directors). Chairman of the Board Filip R. Dierckx was the last director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Upcoming Dividend • May 25Upcoming dividend of €1.37 per shareEligible shareholders must have bought the stock before 01 June 2026. Payment date: 03 June 2026. Payout ratio is a comfortable 41% but the company is not cash flow positive. Trailing yield: 3.9%. Lower than top quartile of Belgian dividend payers (6.5%). Higher than average of industry peers (3.1%).Reported Earnings • Feb 20Third quarter 2026 earnings released: EPS: €1.26 (vs €1.22 in 3Q 2025)Third quarter 2026 results: EPS: €1.26 (up from €1.22 in 3Q 2025). Revenue: €70.8m (up 25% from 3Q 2025). Net income: €46.4m (up 25% from 3Q 2025). Profit margin: 66% (in line with 3Q 2025). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.お知らせ • Feb 20+ 1 more updateGimv NV, Annual General Meeting, May 27, 2026Gimv NV, Annual General Meeting, May 27, 2026.お知らせ • Jan 06Gimv NV to Report First Half, 2026 Results on Sep 03, 2026Gimv NV announced that they will report first half, 2026 results on Sep 03, 2026最新情報をもっと見るRecent updatesお知らせ • Jul 02Impact Healthcare SA acquired an unknown majority stake in Les Psy Réunis SA from Gimv NV (ENXTBR:GIMB).Impact Healthcare SA acquired an unknown majority stake in Les Psy Réunis SA from Gimv NV (ENXTBR:GIMB) on June 30, 2026. Elizabeth and Andrei Cicotti will rollover of their existing stake. Christoph Neeracher, Thomas Rohde, Susanne Schreiber and Martin Leu of Bär & Karrer Ltd. acted as legal advisors for Gimv NV. Stout advised Elizabeth and Andrei Cicotti. Impact Healthcare SA completed the acquisition of an unknown majority stake in Les Psy Réunis SA from Gimv NV (ENXTBR:GIMB) on June 30, 2026.Board Change • Jun 22Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 9 experienced directors. 2 highly experienced directors. 5 independent directors (6 non-independent directors). Chairman of the Board Filip R. Dierckx was the last director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Upcoming Dividend • May 25Upcoming dividend of €1.37 per shareEligible shareholders must have bought the stock before 01 June 2026. Payment date: 03 June 2026. Payout ratio is a comfortable 41% but the company is not cash flow positive. Trailing yield: 3.9%. Lower than top quartile of Belgian dividend payers (6.5%). Higher than average of industry peers (3.1%).Reported Earnings • Feb 20Third quarter 2026 earnings released: EPS: €1.26 (vs €1.22 in 3Q 2025)Third quarter 2026 results: EPS: €1.26 (up from €1.22 in 3Q 2025). Revenue: €70.8m (up 25% from 3Q 2025). Net income: €46.4m (up 25% from 3Q 2025). Profit margin: 66% (in line with 3Q 2025). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.お知らせ • Feb 20+ 1 more updateGimv NV, Annual General Meeting, May 27, 2026Gimv NV, Annual General Meeting, May 27, 2026.お知らせ • Jan 06Gimv NV to Report First Half, 2026 Results on Sep 03, 2026Gimv NV announced that they will report first half, 2026 results on Sep 03, 2026お知らせ • Dec 16Ipsen S.A. (ENXTPA:IPN) completed the acquisition of ImCheck Therapeutics SAS from Kurma Partners SA, Gimv NV (ENXTBR:GIMB) and others.Ipsen S.A. (ENXTPA:IPN) entered into a definitive share purchase agreement to acquire ImCheck Therapeutics SAS from Kurma Partners SA, Gimv NV (ENXTBR:GIMB) and others for €1.4 billion on October 22, 2025. Under the terms of the agreement, through a wholly owned affiliate of Ipsen SAS, shareholders of ImCheck Therapeutics will receive a €350 million payment on a cash-free and debt-free basis at closing of the transaction, and deferred payments contingent upon the achievement of specified regulatory approvals and sales-based milestones, for a total potential consideration up to €1 billion. As a result of this transaction, Gimv will receive an upfront cash payment that represents a realized money multiple of 2.6x on our total investment and a positive impact of approximately €0.4 per share compared to the unaudited NAV communicated in the trading update at the beginning of September. Should all regulatory and sales-based milestones be achieved, this could result in a potential total money multiple of 7.1x, subject to the successful completion of these milestones. The transaction is expected to close by the end of first quarter of 2026, subject to fulfilment of customary closing conditions including the expiration or termination of any required regulatory and governmental approvals under French and U.S. regulations. Marc Castagnède, Olivier Picquerey, Laëtitia Bénard, Charles Tuffreau, Luc Lamblin, Laurie-Anne Ancenys and Charles del Valle of Allen & Overy France acted as legal advisor for Ipsen S.A. Centerview Partners acted as financial advisor for ImCheck Therapeutics SAS. Graham Defries and Kenny Walker-Durrant of Goodwin Procter Llp acted as legal advisor for ImCheck Therapeutics SAS. Dentons Europe, Association d'Avocats à Responsabilité Professionnelle Individuelle acted as legal advisor for ImCheck Therapeutics SAS. Allen & Overy LLP acted as legal advisor for Ipsen S.A. Ipsen S.A. (ENXTPA:IPN) completed the acquisition of ImCheck Therapeutics SAS from Kurma Partners SA, Gimv NV (ENXTBR:GIMB) and others on December 15, 2025.お知らせ • Nov 28Gimv NV (ENXTBR:GIMB) signed an definitive agreement to acquire an unknown minority stake in Equine Care Group from Compagnie Nationale a Portefeuille SA.Gimv NV (ENXTBR:GIMB) signed an definitive agreement to acquire an unknown minority stake in Equine Care Group from Compagnie Nationale a Portefeuille SA on November 27, 2025. By joining CNP, Bencis, the founders, managers and the veterinarians, Gimv becomes part of a very strong shareholder base united behind one ambition: to accelerate ECG’s development into the world’s leading one-stop partner for high-quality equine medicine, and to reinforce ECG’s position as the global leader for veterinary innovation, welfare, and professional excellence.Reported Earnings • Nov 24First half 2026 earnings released: EPS: €3.40 (vs €5.15 in 1H 2025)First half 2026 results: EPS: €3.40 (down from €5.15 in 1H 2025). Revenue: €157.1m (down 16% from 1H 2025). Net income: €126.9m (down 12% from 1H 2025). Profit margin: 81% (up from 77% in 1H 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.お知らせ • Nov 23Gimv NV to Report Fiscal Year 2025 Final Results on Mar 30, 2026Gimv NV announced that they will report fiscal year 2025 final results on Mar 30, 2026お知らせ • Nov 22Gimv NV to Report Nine Months, 2026 Results on Feb 19, 2026Gimv NV announced that they will report nine months, 2026 results on Feb 19, 2026お知らせ • Oct 30Gimv NV to Report First Half, 2026 Results on Nov 20, 2025Gimv NV announced that they will report first half, 2026 results on Nov 20, 2025お知らせ • Oct 22Ipsen S.A. (ENXTPA:IPN) entered into a definitive share purchase agreement to acquire ImCheck Therapeutics SAS from Kurma Partners SA, Gimv NV (ENXTBR:GIMB) and others for €1.4 billion.Ipsen S.A. (ENXTPA:IPN) entered into a definitive share purchase agreement to acquire ImCheck Therapeutics SAS from Kurma Partners SA, Gimv NV (ENXTBR:GIMB) and others for €1.4 billion on October 22, 2025. Under the terms of the agreement, through a wholly owned affiliate of Ipsen SAS, shareholders of ImCheck Therapeutics will receive a €350 million payment on a cash-free and debt-free basis at closing of the transaction, and deferred payments contingent upon the achievement of specified regulatory approvals and sales-based milestones, for a total potential consideration up to €1 billion. As a result of this transaction, Gimv will receive an upfront cash payment that represents a realized money multiple of 2.6x on our total investment and a positive impact of approximately €0.4 per share compared to the unaudited NAV communicated in the trading update at the beginning of September. Should all regulatory and sales-based milestones be achieved, this could result in a potential total money multiple of 7.1x, subject to the successful completion of these milestones. The transaction is expected to close by the end of first quarter of 2026, subject to fulfilment of customary closing conditions including the expiration or termination of any required regulatory and governmental approvals under French and U.S. regulations. Allen & Overy France acted as legal advisor for Ipsen S.A. Centerview Partners acted as financial advisor for ImCheck Therapeutics SAS. Goodwin Procter Llp acted as legal advisor for ImCheck Therapeutics SAS. Dentons Europe, Association d'Avocats à Responsabilité Professionnelle Individuelle acted as legal advisor for ImCheck Therapeutics SAS.お知らせ • Aug 29Gimv NV (ENXTBR:GIMB) entered into an agreement to acquire an unknown majority stake in Novicare B.V. from Gilde Healthcare Partners BV.Gimv NV (ENXTBR:GIMB) entered into an agreement to acquire an unknown majority stake in Novicare B.V. from Gilde Healthcare Partners BV on August 28, 2025. Gimv aims to support Novicare in response to the growing demand for specialized care services. The transaction is subject to customary regulatory approvals including works council approval.お知らせ • Jul 28Gimv NV (ENXTBR:GIMB) and the management of Hemink Groep B.V. completed the acquisition of an unknown majority stake in Hemink Groep B.V. from management and Pontex Investment Partners.Gimv NV (ENXTBR:GIMB) and the management of Hemink Groep B.V. agreed to acquire an unknown majority stake in Hemink Groep B.V. from management and Pontex Investment Partners on July 22, 2025. A cash consideration will be paid by Gimv NV and the management. The management will retain a minority stake in the new structure. Hemink's current management team will co-invest, underlining their long-term commitment to the company's further growth. As part of the acquisition, Hemink will continue to operate under its own identity, with the same people, the same approach and the same ambition. The transaction is subject to customary conditions, including regulatory approvals and approval by the competition authorities. The transaction is expected to close in 2025. Oaklins’ team in the Netherlands acted as the exclusive debt advisor to Gimv. Anke van Holthe tot Echten, Freek Hilberdink, Klaas Wiersma, Louis Lutz and Gianluca Kreuze of Loyens & Loeff acted as legal advisor for Gimv NV. Oaklins N.V. acted as debt advisor to Gimv NV. Bas Stoetzer and Geert Damman of Oaklins’ team in the Netherlands acted as the exclusive debt advisor to Gimv. Gimv NV (ENXTBR:GIMB) and the management of Hemink Groep B.V. completed the acquisition of an unknown majority stake in Hemink Groep B.V. from management and Pontex Investment Partners in July, 2025.お知らせ • Jul 23Gimv NV (ENXTBR:GIMB) and the management of Hemink Groep B.V. agreed to acquire an unknown majority stake in Hemink Groep B.V. from its former management and Pontex Investment Partners.Gimv NV (ENXTBR:GIMB) and the management of Hemink Groep B.V. agreed to acquire an unknown majority stake in Hemink Groep B.V. from its former management and Pontex Investment Partners on July 22, 2025. A cash consideration will be paid by Gimv NV and the management. The management will retain a minority stake in the new structure. Hemink's current management team will co-invest, underlining their long-term commitment to the company's further growth. As part of the acquisition, Hemink will continue to operate under its own identity, with the same people, the same approach and the same ambition. The transaction is subject to customary conditions, including regulatory approvals and approval by the competition authorities. The transaction is expected to close in 2025. Anke van Holthe tot Echten, Freek Hilberdink, Klaas Wiersma, Louis Lutz and Gianluca Kreuze of Loyens & Loeff acted as legal advisor for Gimv NV.Declared Dividend • Jun 27Dividend of €1.82 announcedShareholders will receive a dividend of €1.82. Ex-date: 30th June 2025 Payment date: 25th July 2025 Dividend yield will be 4.1%, which is higher than the industry average of 2.6%. Sustainability & Growth Dividend is covered by earnings (35% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. Earnings per share has grown by 29% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.お知らせ • Jun 25Gimv NV and the management of Alpine Nederland B.V. acquired an unknown majority stake in Alpine Nederland B.V. from Vendis Capital, founders and management of Alpine Nederland B.V.Gimv NV and the management of Alpine Nederland B.V. agreed to acquire an unknown majority stake in Alpine Nederland B.V. from Vendis Capital, founders and management of Alpine Nederland B.V. on June 24, 2025. The management team reinvests part of its proceeds. A cash consideration will be paid by Gimv NV and the management. As part of consideration, an undisclosed value is paid towards common equity of Alpine Nederland B.V. The transaction remains subject to the works council advisory procedure. Floris Pierik of Jones Day (Netherlands) acted as legal advisor to Gimv NV.お知らせ • Jun 24Cobepa S.A. acquired an unknown majority stake in Itineris NV from Participatiemaatschappij Vlaanderen NV, Gimv Arkiv II a fund managed by Gimv NV (ENXTBR:GIMB), SmartFin Capital I a fund managed by SmartFin Capital NV and Federal Holding and Investment Company.Cobepa S.A. acquired an unknown majority stake in Itineris NV from Participatiemaatschappij Vlaanderen NV, Gimv Arkiv II a fund managed by Gimv NV (ENXTBR:GIMB), SmartFin Capital I a fund managed by SmartFin Capital NV and Federal Holding and Investment Company on June 23, 2025. The investment marks a strong vote of confidence in Itineris’ strategy to become the global category leader in advanced software solutions for the utilities sector. Daiwa Corporate Advisory Limited acted as financial advisor for Itineris NV. Allen Overy Shearman Sterling LLP acted as legal advisor for Itineris NV. Four & Five acted as legal advisor for Itineris NV. Cobepa S.A. completed the acquisition of an unknown majority stake in Itineris NV from Participatiemaatschappij Vlaanderen NV, Gimv Arkiv II a fund managed by Gimv NV (ENXTBR:GIMB), SmartFin Capital I a fund managed by SmartFin Capital NV and Federal Holding and Investment Company on June 23, 2025.お知らせ • May 28Bugaboo International B.V. acquired an unknown minority stake in Joolz from Gimv NV (ENXTBR:GIMB).Bugaboo International B.V. acquired an unknown minority stake in Joolz from Gimv NV (ENXTBR:GIMB) on May 27, 2025. Both Joolz and Bugaboo have agreed to join forces to accelerate their international growth in the fragmented worldwide stroller market. Bugaboo International B.V. completed the acquisition of an unknown minority stake in Joolz from Gimv NV (ENXTBR:GIMB) on May 27, 2025.Reported Earnings • May 23Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: €57.2m (up 29% from 3Q 2024). Net income: €37.1m (up 26% from 3Q 2024). Profit margin: 65% (down from 67% in 3Q 2024). The decrease in margin was driven by higher expenses.分析記事 • May 06Insufficient Growth At Gimv NV (EBR:GIMB) Hampers Share PriceWith a price-to-earnings (or "P/E") ratio of 7.2x Gimv NV ( EBR:GIMB ) may be sending bullish signals at the moment...お知らせ • Mar 31Gimv NV to Report Fiscal Year 2025 Results on May 22, 2025Gimv NV announced that they will report fiscal year 2025 results on May 22, 2025New Risk • Mar 12New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 28% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Shareholders have been diluted in the past year (28% increase in shares outstanding).お知らせ • Feb 21Gimv NV agreed to acquired as unknown majority stake in The Spice Factory from Gilde Equity Management and Davy De Muyer.Gimv NV agreed to acquired as unknown majority stake in The Spice Factory from Gilde Equity Management and Davy De Muyer on February 20, 2025. Jorgen De Pelsmaeker, Chief Executive Officer, and the management team will reinvest alongside Gimv as the company embarks on its next phase of growth. Supported by the Gimv, The Spice Factory is expected to strengthen its market position and broaden its international reach. The transaction is expected to close before the end of March 2025.お知らせ • Feb 04Gimv NV (ENXTBR:GIMB) acquired an unknown minority stake in Robojob NV.Gimv NV (ENXTBR:GIMB) acquired an unknown minority stake in Robojob NV on February 3, 2025. The aim of Gimv’s investment is to support RoboJob's international growth and enable the company to realise the full potential of the promising product offering. With this strong foundation complemented with the partnership that Gimv and the De Roovere family are now entering into, RoboJob is now in optimal shape to realise its growth ambitions. Gimv NV (ENXTBR:GIMB) completed the acquisition of an unknown minority stake in Robojob NV on February 3, 2025.お知らせ • Dec 19B+N Referencia Zrt. agreed to acquire an unknown majority stake in Köberl Group from Gimv NV (ENXTBR:GIMB).B+N Referencia Zrt. agreed to acquire an unknown majority stake in Köberl Group from Gimv NV (ENXTBR:GIMB) on December 17, 2024. The deal is expected to close in the first quarter of 2025. Torsten Denker, Philipp Noack, Constantin vom Bauer, Olja Schmitt and Dominik Detels of IMAP Belgium acted as financial advisors for Gimv NV.お知らせ • Dec 06Gimv NV, Eric Merilhou, Yann Dauce and the management of Tibbloc acquired an unknown majority stake in Tibbloc from Ciclad, SAS.Gimv NV, Eric Merilhou, Yann Dauce and the management of Tibbloc acquired an unknown majority stake in Tibbloc from Ciclad, SAS on December 4, 2024. A cash consideration will be paid by Gimv NV and the management. As part of consideration, an undisclosed value is paid towards common equity of Tibbloc. For the period ending December 31, 2023, Tibbloc reported total revenue of €40 million. Gimv NV, Eric Merilhou, Yann Dauce and the management of Tibbloc completed the acqusition of an unknown majority stake in Tibbloc from Ciclad, SAS on December 4, 2024.お知らせ • Dec 04Gimv NV (ENXTBR:GIMB) and Wolf D. Koch agreed to acquire an unknown majority stake in Lupine Lighting Systems GmbH from Wolf D. Koch.Gimv NV (ENXTBR:GIMB) and Wolf D. Koch agreed to acquire an unknown majority stake in Lupine Lighting Systems GmbH from Wolf D. Koch on December 2, 2024. Wolf D. Koch, founder and chief executive officer, reinvesting part of his proceeds to hold a minority stake in the company. Financial details of the transaction remain undisclosed, pending successful closure.分析記事 • Nov 27Benign Growth For Gimv NV (EBR:GIMB) Underpins Its Share PriceWhen close to half the companies in Belgium have price-to-earnings ratios (or "P/E's") above 14x, you may consider Gimv...Reported Earnings • Nov 26First half 2025 earnings released: EPS: €5.15 (vs €5.81 in 1H 2024)First half 2025 results: EPS: €5.15 (down from €5.81 in 1H 2024). Revenue: €187.3m (down 7.9% from 1H 2024). Net income: €144.9m (down 8.4% from 1H 2024). Profit margin: 77% (in line with 1H 2024). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.お知らせ • Nov 22Fremman Limited agreed to acquire an unknown majority stake in rehaneo GmbH from Gimv NV (ENXTBR:GIMB).Fremman Limited agreed to acquire an unknown majority stake in rehaneo GmbH from Gimv NV (ENXTBR:GIMB) on November 20, 2024. The financing will be provided by Ares. Founder and chief executive officer Bruno Crone and co-founder and Chief operating officer Christoph Dühr remain significantly invested in the company and continue their management roles. The transaction is subject to approval by the German antitrust authorities and is expected to close in Q1 2025. Isabell Hitzer and Dr. Bernd Egbers of Astera Legal acted as legal advisor for Fremman Limited. Latham & Watkins acted as legal advisor to Ares.お知らせ • Oct 16The Martens Brewery of Bocholt acquired United Dutch Breweries B.V. from Gimv NV (ENXTBR:GIMB) and management.The Martens Brewery of Bocholt acquired United Dutch Breweries B.V. from Gimv NV (ENXTBR:GIMB) and management on October 16, 2024. The Martens Brewery of Bocholt completed the acquisition of United Dutch Breweries B.V. from Gimv NV (ENXTBR:GIMB) and management on October 16, 2024.お知らせ • Sep 06BiZZdesign BV agreed to acquire MEGA International S.A. from Gimv NV (ENXTBR:GIMB).BiZZdesign BV agreed to acquire MEGA International S.A. from Gimv NV (ENXTBR:GIMB) on September 4, 2024. The transaction is subject to approval by regulatory board / committee.Upcoming Dividend • Jun 24Upcoming dividend of €1.82 per shareEligible shareholders must have bought the stock before 01 July 2024. Payment date: 26 July 2024. Payout ratio is a comfortable 33% but the company is not cash flow positive. Trailing yield: 5.7%. Lower than top quartile of Belgian dividend payers (7.2%). Higher than average of industry peers (3.0%).New Risk • Jun 10New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Paying a dividend despite having no free cash flows. Shareholders have been diluted in the past year (2.4% increase in shares outstanding).お知らせ • May 22WorxInvest NV completed the acquisition of 27.81% stake in Gimv NV (ENXTBR:GIMB) from Flemish Community.WorxInvest NV signed an agreement to acquire 27.81% stake in Gimv NV (ENXTBR:GIMB) from Flemish Community for approximately €370 million on November 30, 2023. The transaction is subject to customary regulatory approvals., Freshfields Bruckhaus Deringer LLP and Ernst & Young served as accountant to WorxInvest on the transaction. Rothschild & Co and Stibbe advised the Flemish Region on the transaction. Morgan Stanley acted as financial advisor to WorxInvest NV. Koen Vanhaerents, Guillaume Nataf, Frans Muller and Bram Hoorelbeke of Baker & Mckenzie acted as legal advisor to Gimv. As of April 15, 2024, The European Commission approved WorxInvest to buy Gimv.WorxInvest NV completed the acquisition of 27.81% stake in Gimv NV (ENXTBR:GIMB) from Flemish Community on May 21, 2024. All regulatory approvals obtained.お知らせ • Feb 28Sagard SAS acquired Groupe Acceo from Gimv NV (ENXTBR:GIMB).Sagard SAS acquired Groupe Acceo from Gimv NV (ENXTBR:GIMB) on February 27, 2024. Moncey Avocats acted as legal advisor, Natixis Partners and UBS M & A Mid-Cap acted as financial advisor, KPMG Corporate Finance France, Indefi and Marsh & Mclennan Companies France acted as due diligence provider to Sagard SAS. Capitalmind Corporate Finance Advisory acted as financial advisor, Hogan Lovells (Paris) LLP acted as legal advisor, Oderis Consulting and EY-Parthenon acted as due diligence provider to Groupe Acceo shareholders. Sagard SAS completed the acquisition of Groupe Acceo from Gimv NV (ENXTBR:GIMB) on February 27, 2024.お知らせ • Feb 03+ 2 more updatesGimv NV to Report Fiscal Year 2024 Results on May 23, 2024Gimv NV announced that they will report fiscal year 2024 results on May 23, 2024Reported Earnings • Nov 26First half 2024 earnings released: EPS: €5.81 (vs €2.80 loss in 1H 2023)First half 2024 results: EPS: €5.81 (up from €2.80 loss in 1H 2023). Revenue: €203.3m (up 86% from 1H 2023). Net income: €158.2m (up €233.2m from 1H 2023). Profit margin: 78% (up from net loss in 1H 2023). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.お知らせ • Sep 19Crédit Mutuel Equity signed an agreement to acquire unknown majority stake in Groupe CLAIRE SAS from Gimv NV (ENXTBR:GIMB).Crédit Mutuel Equity signed an agreement to acquire unknown majority stake in Groupe CLAIRE SAS from Gimv NV (ENXTBR:GIMB) on September 18, 2023. Completion of the transaction remains subject to the recommendation of Groupe Claire's employee representative bodies, as well as the authorization of the French Competition Authority.Reported Earnings • May 21Full year 2023 earnings released: €2.20 loss per share (vs €6.59 profit in FY 2022)Full year 2023 results: €2.20 loss per share (down from €6.59 profit in FY 2022). Net loss: €59.5m (down 134% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.Reported Earnings • Jan 11First half 2023 earnings released: €2.80 loss per share (vs €5.22 profit in 1H 2022)First half 2023 results: €2.80 loss per share (down from €5.22 profit in 1H 2022). Revenue: €109.3m (down 48% from 1H 2022). Net loss: €75.1m (down 155% from profit in 1H 2022). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.お知らせ • Dec 10Management of Biolam acquired an unknown minority stake in Biolam from Gimv NV (ENXTBR:GIMB).Management of Biolam acquired an unknown minority stake in Biolam from Gimv NV (ENXTBR:GIMB) on December 9, 2022. Gimv is selling its stake in Biolam to its founding team, backed by private equity investors. Management of Biolam completed the acquisition of an unknown minority stake in Biolam from Gimv NV (ENXTBR:GIMB) on December 9, 2022.Buying Opportunity • Nov 21Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 18%. The fair value is estimated to be €54.34, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last 3 years. Earnings per share has grown by 47%.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Frank Verhaegen was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Buying Opportunity • Nov 01Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 17%. The fair value is estimated to be €54.62, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last 3 years. Earnings per share has grown by 47%.お知らせ • Oct 26Gimv NV to Report Fiscal Year 2023 Results on May 17, 2023Gimv NV announced that they will report fiscal year 2023 results on May 17, 2023お知らせ • Oct 19Gimv NV, Annual General Meeting, Jun 28, 2023Gimv NV, Annual General Meeting, Jun 28, 2023.Buying Opportunity • Aug 02Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 6.0%. The fair value is estimated to be €64.89, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last 3 years. Earnings per share has grown by 47%.Buying Opportunity • Jun 22Now 20% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be €65.65, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last 3 years. Earnings per share has grown by 47%.お知らせ • Jun 10GIMV NV (ENXTBR:GIMB) acquired 30% stake in Picot SA.GIMV NV (ENXTBR:GIMB) acquired 30% stake in Picot SA on June 9, 2022. Picot SA's shareholders and management will join GIMV NV. At the end of 2021, Picot had a turnover of €212 million. GIMV NV (ENXTBR:GIMB) completed the acquisition of 30% stake in Picot SA on June 9, 2022.お知らせ • May 13GIMV NV (ENXTBR:GIMB) completed the acquisition of 20.87% stake in Bioconnection B.V. from Pharming Group N.V. (ENXTAM:PHARM).GIMV NV (ENXTBR:GIMB) reached an agreement to acquire 20.87% stake in Bioconnection B.V. from Pharming Group N.V. (ENXTAM:PHARM) for €6.9 million on April 22, 2022. Pharming will receive one-off €6.9 million net cash proceeds in Q2 2022. Pharming will continue to support BioConnection to accelerate its next stage of growth to further invest in its organization and infrastructure to increase the production capacity. GIMV NV (ENXTBR:GIMB) completed the acquisition of 20.87% stake in Bioconnection B.V. from Pharming Group N.V. (ENXTAM:PHARM) on May 12, 2022.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 2 highly experienced directors. Independent Director Frank Verhaegen was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Apr 23GIMV NV (ENXTBR:GIMB) reached an agreement to acquire 20.87% stake in Bioconnection B.V. from Pharming Group N.V. (ENXTAM:PHARM) for ?6.9 million.GIMV NV (ENXTBR:GIMB) reached an agreement to acquire 20.87% stake in Bioconnection B.V. from Pharming Group N.V. (ENXTAM:PHARM) for ?6.9 million on April 22, 2022. Pharming will receive one-off ?6.9 million net cash proceeds in Q2 2022. Pharming will continue to support BioConnection to accelerate its next stage of growth to further invest in its organization and infrastructure to increase the production capacity.お知らせ • Apr 01STRACO acquired an unknown majority stake in Incendin NV from GIMV NV (ENXTBR:GIMB).STRACO acquired an unknown majority stake in Incendin NV from GIMV NV (ENXTBR:GIMB) on March 30, 2022. STRACO completed the acquisition of an unknown majority stake in Incendin NV from GIMV NV (ENXTBR:GIMB) on March 30, 2022.Buying Opportunity • Feb 22Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 2.8%. The fair value is estimated to be €65.82, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% per annum over the last 3 years. The company has become profitable over the last year.Price Target Changed • Dec 06Price target increased to €56.75Up from €53.00, the current price target is provided by 1 analyst. New target price is 5.9% above last closing price of €53.60. Stock is up 8.1% over the past year. The company posted earnings per share of €7.96 last year.Reported Earnings • Nov 21First half 2022 earnings released: EPS €5.22 (vs €3.61 in 1H 2021)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2022 results: Revenue: €208.5m (up 21% from 1H 2021). Net income: €137.0m (up 46% from 1H 2021). Profit margin: 66% (up from 55% in 1H 2021). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.Reported Earnings • May 22Full year 2021 earnings released: EPS €7.96 (vs €5.96 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: €331.9m (up 125% from FY 2020). Net income: €205.7m (up €357.3m from FY 2020). Profit margin: 62% (up from net loss in FY 2020). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.お知らせ • May 01GIMV NV (ENXTBR:GIMB) agreed to acquire an unknown minority stake in Projective NV.GIMV NV (ENXTBR:GIMB) agreed to acquire an unknown minority stake in Projective NV on April 29, 2021. The current partners and shareholders of the Projective Group will remain on board and retain the majority of the shares. For the year ended 2020, Projective reported a revenue of €45 million. The transaction is subject to customary closing conditions. Klaas Thibaut, Wout Hooyberghs and Cody Demuytere of Quinz acted as legal advisor for GIMV NV.お知らせ • Mar 19+ 1 more updateGIMV NV (ENXTBR:GIMB) along with the management agreed to acquire an unknown majority stake in Verkley B.V. from PMH Investments.GIMV NV (ENXTBR:GIMB) along with the management agreed to acquire an unknown majority stake in Verkley B.V. from PMH Investments on March 17, 2021. In 2020, Verkley B.V. reported a total revenues of €38 million out of two facilitates one in Drachten (head office) and one in Groningen. The transaction is subject to customary closing conditions, including approval by the competition authorities.Is New 90 Day High Low • Feb 26New 90-day low: €48.50The company is down 3.0% from its price of €49.75 on 27 November 2020. The Belgian market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Capital Markets industry, which is up 2.0% over the same period.分析記事 • Feb 08How Does GIMV NV (EBR:GIMB) Fare As A Dividend Stock?Is GIMV NV ( EBR:GIMB ) a good dividend stock? How can we tell? Dividend paying companies with growing earnings can be...Is New 90 Day High Low • Feb 03New 90-day high: €51.20The company is up 10.0% from its price of €46.35 on 04 November 2020. The Belgian market is up 16% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Capital Markets industry, which is up 9.0% over the same period.お知らせ • Jan 20Belden Inc. (NYSE:BDC) entered into a definitive agreement to acquire OTN Systems N.V. from GIMV NV (ENXTBR:GIMB), Manuardeo and management for approximately $71 million.Belden Inc. (NYSE:BDC) entered into a definitive agreement to acquire OTN Systems N.V. from GIMV NV (ENXTBR:GIMB), Manuardeo and management for approximately $71 million on January 19, 2021. The transaction will be financed with cash on hand, which was approximately $500 million at the end of 2020. The transaction is subject to customary closing conditions and is expected to close in the first quarter 2021. The transaction has a positive impact of about $18.2 million (€15 million) on Gimv's net asset value as per September 30, 2020. The return over the entire investment period exceeds Gimv's long-term average.Is New 90 Day High Low • Dec 28New 90-day high: €50.70The company is up 5.0% from its price of €48.20 on 29 September 2020. The Belgian market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Capital Markets industry, which is up 13% over the same period.分析記事 • Dec 18Would Shareholders Who Purchased GIMV's (EBR:GIMB) Stock Year Be Happy With The Share price Today?Most people feel a little frustrated if a stock they own goes down in price. But sometimes a share price fall can have...お知らせ • Dec 03Parcom Capital has reached an agreement to acquire majority stake in CFL Holding BV from GIMV NV (ENXTBR:GIMB).Parcom Capital has reached an agreement to acquire majority stake in CFL Holding BV from GIMV NV (ENXTBR:GIMB) on December 2, 2020. Bas Korte remains on board as group Chief Executive Officer. Parcom will support management with their continued value creation by focusing on the large opportunity in the energy transition of the residential building market. The transaction is subject to customary closing condition, including approval by regulatory authorities and competition authorities. Acquisition is expected to close early 2021. Transaction which represents the exit of the largest shareholding on Gimv's balance sheet, has a positive impact of about €20 million on Gimv's net asset value as per September 30, 2020.Reported Earnings • Nov 22First half 2021 earnings released: EPS €3.61The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: €172.5m (up 12% from 1H 2020). Net income: €94.0m (up 83% from 1H 2020). Profit margin: 55% (up from 33% in 1H 2020). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 81% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.お知らせ • Nov 20+ 1 more updateGIMV NV, Annual General Meeting, Jun 30, 2021GIMV NV, Annual General Meeting, Jun 30, 2021.Is New 90 Day High Low • Nov 19New 90-day high: €48.90The company is up 7.0% from its price of €45.60 on 21 August 2020. The Belgian market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Capital Markets industry, which is up 6.0% over the same period.Is New 90 Day High Low • Oct 21New 90-day low: €45.45The company is down 4.0% from its price of €47.15 on 23 July 2020. The Belgian market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Capital Markets industry, which is down 1.0% over the same period.お知らせ • Sep 30+ 1 more updateManagement of Ecu-Line and Allcargo acquired 100% stake in Ecu-Line from ABN AMRO and GIMV.Management of Ecu-Line and Allcargo acquired 100% stake in Ecu-Line from ABN AMRO and GIMV on June 16, 2005. The terms were not disclosed. For the year ended on December 31, 2004, Ecu-Line had consolidated sales of more than €180 million. Raymond Van Achteren, Marc Van Looveren and Kris De Witte (the management of Ecu-Line) has acquired majority stake and Allcargo acquired the minority stake. Deloitte Corporate Finance Belgium served as financial advisor and Laga & Philippe served as legal advisor to the management. Management of Ecu-Line and Allcargo completed the acquisition of 100% stake in Ecu-Line from ABN AMRO and GIMV on June 16, 2005.お知らせ • Sep 25+ 2 more updatesKatoen Natie acquired Nieuwe Havema N.V. from GIMV, Mercator and other shareholders.Nieuwe Havema N.V. was acquired by Katoen Natie on September 16, 2003. GIMV and Mercator sold their stakes in Nieuwe Havema through the transaction. Sequoia Consulting BVBA acted as financial advisor to Werf en Vlasnatie N.V. Katoen Natie completed the acquisition of Nieuwe Havema N.V. on September 16, 2003.お知らせ • Sep 23Individuals announced the acquisition of 40% stake in Begro N.V. from GIMV NV.GIMV NV (ENXTBR: GIMB) announced that it has agreed to sell it 40% stake in Begro N.V. to the individuals in 2001.お知らせ • Aug 28An undisclosed buyer acquired an unknown stake in Govecs AG from GIMV NV (ENXTBR:GIMB).An undisclosed buyer acquired an unknown stake in Govecs AG from GIMV NV (ENXTBR:GIMB) in 2014. An undisclosed buyer completed the acquisition of an unknown stake in Govecs AG from GIMV NV (ENXTBR:GIMB) in 2014.お知らせ • Aug 27The management of PROXIAD Group S.A.S. acquired an unknown stake in PROXIAD Group S.A.S. from GIMV NV (ENXTBR:GIMB).The management of PROXIAD Group S.A.S. acquired an unknown stake in PROXIAD Group S.A.S. from GIMV NV (ENXTBR:GIMB) in April 2015. The management of PROXIAD Group S.A.S. completed the acquisition of an unknown stake in PROXIAD Group S.A.S. from GIMV NV (ENXTBR:GIMB) in April 2015.お知らせ • Aug 21Babyshop Sthlm AB acquired BEBEO SA from GIMV NV (ENXTBR:GIMB) and Nathalie Genty.Babyshop Sthlm AB acquired BEBEO SA from GIMV NV (ENXTBR:GIMB) and Nathalie Genty on August 20, 2020. GIMV and Nathalie Genty will join as shareholders of Melijoe. Melijoe will continue to trade separately and benefit from the capabilities of the group. Melijoe had revenue in excess of €20 million. GIMV and Nathalie Genty will stay on board. Carnegie Investment Bank acted as sole financial advisor for Babyshop Sthlm AB. Babyshop Sthlm AB completed the acquisition of BEBEO SA from GIMV NV (ENXTBR:GIMB) and Nathalie Genty on August 20, 2020.お知らせ • Jul 01Tosca Services, LLC agreed to acquire Contraload NV from founders(Sylvain Naets and Jesse Sels) along with Down2Earth fund managed by Down 2 Earth Capital NV and GIMV NV (ENXTBR:GIMB).Tosca Services, LLC agreed to acquire Contraload NV from founders (Sylvain Naets and Jesse Sels) along with Down2Earth fund managed by Down 2 Earth Capital NV and GIMV NV (ENXTBR:GIMB) on June 29, 2020. In conjunction with the transaction, funds advised by Apax Partner, which acquired Tosca in 2017, will commit additional capital to Tosca to fund the acquisition of Contraload NV. Contraload reported sales of €46 million for the year 2019. Contraload's team will join Tosca Services group through this transaction. Ben Schaye, Ryerson Symons, Jonathan Goldstein, Adam D. Shapiro, Sara Y. Razi, David E. Vann, Derek Baird, Ellen L. Frye, Patricia K. Adams, Lori E. Lesser, Genevieve Dorment, Steven R. DeLott, Michael R. Isby of Simpson Thacher & Bartlett LLP acted as legal advisors to Tosca Services, LLC and Apax Partners LLP.株主還元GIMBBE Capital MarketsBE 市場7D0%-0.3%-0.6%1Y5.5%-2.7%22.4%株主還元を見る業界別リターン: GIMB過去 1 年間で-2.7 % の収益を上げたBelgian Capital Markets業界を上回りました。リターン対市場: GIMBは、過去 1 年間で22.4 % のリターンを上げたBelgian市場を下回りました。価格変動Is GIMB's price volatile compared to industry and market?GIMB volatilityGIMB Average Weekly Movement2.8%Capital Markets Industry Average Movement2.6%Market Average Movement3.7%10% most volatile stocks in BE Market7.2%10% least volatile stocks in BE Market2.2%安定した株価: GIMB 、 Belgian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: GIMBの 週次ボラティリティ ( 3% ) は過去 1 年間安定しています。会社概要設立従業員CEO(最高経営責任者ウェブサイト198095Koen Dejonckheerewww.gimv.com/en/ギムヴNVは、直接投資とファンド・オブ・ファンズ投資を専門とするプライベート・エクイティおよびベンチャー・キャピタル会社である。直接投資では、バイアウト、グロース・キャピタル、ミドル・マーケット、デット、株主ローン、シード、スタートアップ、アーリーからミドル・ステージ、レイト・ベンチャー、パブリックからプライベートへの取引、中小企業、レイト・ステージ、成熟期、リプレイス・キャピタル、ブリッジ・ファイナンス、資本増強を専門としている。ファンド・オブ・ファンズの中では、ベンチャー・キャピタルとプライベート・エクイティ・ファンドへの投資を目指している。同社は、買収を通じて社内の成長を加速させることができる対応力のある高業績成長企業への投資を目指している。一般的には、コンシューマー、コネクテッド・コンシューマー、フィンテック、ヘルスケア、スマート・インダストリー、サステイナブル・シティに投資している。コンシューマー分野では、新興のリーダー企業に成長資金を提供することを目指している。ヘルスケア・プラットフォームでは、有機的に、あるいはバイ・アンド・ビルド戦略によって成長できる企業への投資を目指す。消費者関連では、消費財、食品・飲料、健康食品、スポーツ、コンビニエンス・フード、パーソナル・ラグジュアリー、キャリア、ホーム&インテリア、ベビー&キッズ、ペット用品、小売、消費者サービス、メディア・コンテンツ、旅行・レジャー、教育、デジタル・エコノミー、オンライン分野に注力している。医療・介護分野では、ライフサイエンス、医療技術、医療・介護サービスに注力している。医薬品、プラットフォーム技術、ワクチン、診断テスト、前臨床、初期臨床、後期臨床からなるバイオテクノロジー/バイオファーマ、医療機器、消耗品、IT、小型機器などの医療技術、医療・介護サービスをベースとする企業に重点を置いている。また、積極的な株主となることを目指し、できれば投資案件のリードまたは共同リードを務める。スマート産業分野では、資源効率の高い開発・生産のための機器・サービス・ツール、自動車・航空宇宙、既存の輸送手段の最適化と新たな輸送手段の開発、クラウドの柔軟性を活用したソフトウェアとサービス、スマート・データ管理、高度な計算能力、生産・貯蔵・管理・使用・輸送の各分野におけるエネルギーの効率的利用のためのコンポーネントとシステムなどに重点を置いている。イノベーション、高度なエンジニアリング、高度な製造、ソフトウェアに基づくB2Bの製品やサービスに重点を置いている。また、株式投資(エクイティ、準エクイティ、マイノリティ、マジョリティ)にも柔軟に対応しますが、常に企業に有意義な影響を与え、出口を見据えた投資を行います。持続可能な都市では、持続可能な都市社会を構築するための製品、サービス、インフラに重点を置いている:エネルギーおよびその他(原材料)関連の公益事業および消費財、廃棄物処理、リサイクルおよび回収、建設およびインフラ、輸送および物流サービス、バイオマス、グリーン(持続可能)ケミストリー、水、オフショアおよび海洋ソリューション、エネルギー効率の高いインフラ。メザニン、エクイティ、マイノリティ、マジョリティ)を通じて投資するが、常に企業の戦略に有意義な影響を与えるよう努め、エグジットのきっかけを必要とする。また、半導体、化学、農業、クリーンテクノロジー、エレクトロニクス、水処理、浄化技術などにも投資している。主にフランダースとブリュッセルの欧州市場および中堅企業に焦点を当て、カザフスタン、ベネルクス、ドイツ、フランス、イタリア、ルクセンブルク、オランダ、英国、ロシア、チェコ共和国、スロバキアにも投資し、主にベネルクス、フランス、ドイツに本社を置く中小企業に投資している。通常、500万ユーロ(543万ドル)から7,500万ユーロ(8,153万ドル)の間で、消費財、ヘルスケア、スマート産業、持続可能な顧客セクターへの投資を行う。投資先企業の株式の過半数を取得することもあれば、少数株式を取得することもある。投資期間は4年から7年。また、投資先企業の取締役も務める。ギムヴは、自社のバランスシートからの資本と様々な運用ファンドを通じて投資を行っている。ギムヴNVは1980年2月25日に設立され、ベルギーのアントワープを拠点に、フランスのパリ、オランダのハーグ、ドイツのフランクフルト・アム・マイン、イギリスのロンドン、チェコ共和国のプラハ、ポーランドのワルシャワ、ドイツのミュンヘンにオフィスを構えている。もっと見るGimv NV 基礎のまとめGimv の収益と売上を時価総額と比較するとどうか。GIMB 基礎統計学時価総額€1.64b収益(TTM)€231.08m売上高(TTM)€302.10m7.1xPER(株価収益率5.4xP/SレシオGIMB は割高か?公正価値と評価分析を参照収益と収入最新の決算報告書(TTM)に基づく主な収益性統計GIMB 損益計算書(TTM)収益€302.10m売上原価€13.55m売上総利益€288.55mその他の費用€57.46m収益€231.08m直近の収益報告Dec 31, 2025次回決算日Sep 03, 2026一株当たり利益(EPS)6.29グロス・マージン95.51%純利益率76.49%有利子負債/自己資本比率17.5%GIMB の長期的なパフォーマンスは?過去の実績と比較を見る配当金4.4%現在の配当利回り41%配当性向View Valuation企業分析と財務データの現状データ最終更新日(UTC時間)企業分析2026/07/16 09:38終値2026/07/16 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM(Trailing Twelve Month)またはLTM(Last Twelve Month)データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Gimv NV 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6 アナリスト機関Olivier Van DoosselaereBNP ParibasAlexi GantelmeBNP ParibasKris KippersDegroof Petercam3 その他のアナリストを表示
お知らせ • Jul 02Impact Healthcare SA acquired an unknown majority stake in Les Psy Réunis SA from Gimv NV (ENXTBR:GIMB).Impact Healthcare SA acquired an unknown majority stake in Les Psy Réunis SA from Gimv NV (ENXTBR:GIMB) on June 30, 2026. Elizabeth and Andrei Cicotti will rollover of their existing stake. Christoph Neeracher, Thomas Rohde, Susanne Schreiber and Martin Leu of Bär & Karrer Ltd. acted as legal advisors for Gimv NV. Stout advised Elizabeth and Andrei Cicotti. Impact Healthcare SA completed the acquisition of an unknown majority stake in Les Psy Réunis SA from Gimv NV (ENXTBR:GIMB) on June 30, 2026.
Board Change • Jun 22Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 9 experienced directors. 2 highly experienced directors. 5 independent directors (6 non-independent directors). Chairman of the Board Filip R. Dierckx was the last director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Upcoming Dividend • May 25Upcoming dividend of €1.37 per shareEligible shareholders must have bought the stock before 01 June 2026. Payment date: 03 June 2026. Payout ratio is a comfortable 41% but the company is not cash flow positive. Trailing yield: 3.9%. Lower than top quartile of Belgian dividend payers (6.5%). Higher than average of industry peers (3.1%).
Reported Earnings • Feb 20Third quarter 2026 earnings released: EPS: €1.26 (vs €1.22 in 3Q 2025)Third quarter 2026 results: EPS: €1.26 (up from €1.22 in 3Q 2025). Revenue: €70.8m (up 25% from 3Q 2025). Net income: €46.4m (up 25% from 3Q 2025). Profit margin: 66% (in line with 3Q 2025). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
お知らせ • Feb 20+ 1 more updateGimv NV, Annual General Meeting, May 27, 2026Gimv NV, Annual General Meeting, May 27, 2026.
お知らせ • Jan 06Gimv NV to Report First Half, 2026 Results on Sep 03, 2026Gimv NV announced that they will report first half, 2026 results on Sep 03, 2026
お知らせ • Jul 02Impact Healthcare SA acquired an unknown majority stake in Les Psy Réunis SA from Gimv NV (ENXTBR:GIMB).Impact Healthcare SA acquired an unknown majority stake in Les Psy Réunis SA from Gimv NV (ENXTBR:GIMB) on June 30, 2026. Elizabeth and Andrei Cicotti will rollover of their existing stake. Christoph Neeracher, Thomas Rohde, Susanne Schreiber and Martin Leu of Bär & Karrer Ltd. acted as legal advisors for Gimv NV. Stout advised Elizabeth and Andrei Cicotti. Impact Healthcare SA completed the acquisition of an unknown majority stake in Les Psy Réunis SA from Gimv NV (ENXTBR:GIMB) on June 30, 2026.
Board Change • Jun 22Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 9 experienced directors. 2 highly experienced directors. 5 independent directors (6 non-independent directors). Chairman of the Board Filip R. Dierckx was the last director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Upcoming Dividend • May 25Upcoming dividend of €1.37 per shareEligible shareholders must have bought the stock before 01 June 2026. Payment date: 03 June 2026. Payout ratio is a comfortable 41% but the company is not cash flow positive. Trailing yield: 3.9%. Lower than top quartile of Belgian dividend payers (6.5%). Higher than average of industry peers (3.1%).
Reported Earnings • Feb 20Third quarter 2026 earnings released: EPS: €1.26 (vs €1.22 in 3Q 2025)Third quarter 2026 results: EPS: €1.26 (up from €1.22 in 3Q 2025). Revenue: €70.8m (up 25% from 3Q 2025). Net income: €46.4m (up 25% from 3Q 2025). Profit margin: 66% (in line with 3Q 2025). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
お知らせ • Feb 20+ 1 more updateGimv NV, Annual General Meeting, May 27, 2026Gimv NV, Annual General Meeting, May 27, 2026.
お知らせ • Jan 06Gimv NV to Report First Half, 2026 Results on Sep 03, 2026Gimv NV announced that they will report first half, 2026 results on Sep 03, 2026
お知らせ • Dec 16Ipsen S.A. (ENXTPA:IPN) completed the acquisition of ImCheck Therapeutics SAS from Kurma Partners SA, Gimv NV (ENXTBR:GIMB) and others.Ipsen S.A. (ENXTPA:IPN) entered into a definitive share purchase agreement to acquire ImCheck Therapeutics SAS from Kurma Partners SA, Gimv NV (ENXTBR:GIMB) and others for €1.4 billion on October 22, 2025. Under the terms of the agreement, through a wholly owned affiliate of Ipsen SAS, shareholders of ImCheck Therapeutics will receive a €350 million payment on a cash-free and debt-free basis at closing of the transaction, and deferred payments contingent upon the achievement of specified regulatory approvals and sales-based milestones, for a total potential consideration up to €1 billion. As a result of this transaction, Gimv will receive an upfront cash payment that represents a realized money multiple of 2.6x on our total investment and a positive impact of approximately €0.4 per share compared to the unaudited NAV communicated in the trading update at the beginning of September. Should all regulatory and sales-based milestones be achieved, this could result in a potential total money multiple of 7.1x, subject to the successful completion of these milestones. The transaction is expected to close by the end of first quarter of 2026, subject to fulfilment of customary closing conditions including the expiration or termination of any required regulatory and governmental approvals under French and U.S. regulations. Marc Castagnède, Olivier Picquerey, Laëtitia Bénard, Charles Tuffreau, Luc Lamblin, Laurie-Anne Ancenys and Charles del Valle of Allen & Overy France acted as legal advisor for Ipsen S.A. Centerview Partners acted as financial advisor for ImCheck Therapeutics SAS. Graham Defries and Kenny Walker-Durrant of Goodwin Procter Llp acted as legal advisor for ImCheck Therapeutics SAS. Dentons Europe, Association d'Avocats à Responsabilité Professionnelle Individuelle acted as legal advisor for ImCheck Therapeutics SAS. Allen & Overy LLP acted as legal advisor for Ipsen S.A. Ipsen S.A. (ENXTPA:IPN) completed the acquisition of ImCheck Therapeutics SAS from Kurma Partners SA, Gimv NV (ENXTBR:GIMB) and others on December 15, 2025.
お知らせ • Nov 28Gimv NV (ENXTBR:GIMB) signed an definitive agreement to acquire an unknown minority stake in Equine Care Group from Compagnie Nationale a Portefeuille SA.Gimv NV (ENXTBR:GIMB) signed an definitive agreement to acquire an unknown minority stake in Equine Care Group from Compagnie Nationale a Portefeuille SA on November 27, 2025. By joining CNP, Bencis, the founders, managers and the veterinarians, Gimv becomes part of a very strong shareholder base united behind one ambition: to accelerate ECG’s development into the world’s leading one-stop partner for high-quality equine medicine, and to reinforce ECG’s position as the global leader for veterinary innovation, welfare, and professional excellence.
Reported Earnings • Nov 24First half 2026 earnings released: EPS: €3.40 (vs €5.15 in 1H 2025)First half 2026 results: EPS: €3.40 (down from €5.15 in 1H 2025). Revenue: €157.1m (down 16% from 1H 2025). Net income: €126.9m (down 12% from 1H 2025). Profit margin: 81% (up from 77% in 1H 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
お知らせ • Nov 23Gimv NV to Report Fiscal Year 2025 Final Results on Mar 30, 2026Gimv NV announced that they will report fiscal year 2025 final results on Mar 30, 2026
お知らせ • Nov 22Gimv NV to Report Nine Months, 2026 Results on Feb 19, 2026Gimv NV announced that they will report nine months, 2026 results on Feb 19, 2026
お知らせ • Oct 30Gimv NV to Report First Half, 2026 Results on Nov 20, 2025Gimv NV announced that they will report first half, 2026 results on Nov 20, 2025
お知らせ • Oct 22Ipsen S.A. (ENXTPA:IPN) entered into a definitive share purchase agreement to acquire ImCheck Therapeutics SAS from Kurma Partners SA, Gimv NV (ENXTBR:GIMB) and others for €1.4 billion.Ipsen S.A. (ENXTPA:IPN) entered into a definitive share purchase agreement to acquire ImCheck Therapeutics SAS from Kurma Partners SA, Gimv NV (ENXTBR:GIMB) and others for €1.4 billion on October 22, 2025. Under the terms of the agreement, through a wholly owned affiliate of Ipsen SAS, shareholders of ImCheck Therapeutics will receive a €350 million payment on a cash-free and debt-free basis at closing of the transaction, and deferred payments contingent upon the achievement of specified regulatory approvals and sales-based milestones, for a total potential consideration up to €1 billion. As a result of this transaction, Gimv will receive an upfront cash payment that represents a realized money multiple of 2.6x on our total investment and a positive impact of approximately €0.4 per share compared to the unaudited NAV communicated in the trading update at the beginning of September. Should all regulatory and sales-based milestones be achieved, this could result in a potential total money multiple of 7.1x, subject to the successful completion of these milestones. The transaction is expected to close by the end of first quarter of 2026, subject to fulfilment of customary closing conditions including the expiration or termination of any required regulatory and governmental approvals under French and U.S. regulations. Allen & Overy France acted as legal advisor for Ipsen S.A. Centerview Partners acted as financial advisor for ImCheck Therapeutics SAS. Goodwin Procter Llp acted as legal advisor for ImCheck Therapeutics SAS. Dentons Europe, Association d'Avocats à Responsabilité Professionnelle Individuelle acted as legal advisor for ImCheck Therapeutics SAS.
お知らせ • Aug 29Gimv NV (ENXTBR:GIMB) entered into an agreement to acquire an unknown majority stake in Novicare B.V. from Gilde Healthcare Partners BV.Gimv NV (ENXTBR:GIMB) entered into an agreement to acquire an unknown majority stake in Novicare B.V. from Gilde Healthcare Partners BV on August 28, 2025. Gimv aims to support Novicare in response to the growing demand for specialized care services. The transaction is subject to customary regulatory approvals including works council approval.
お知らせ • Jul 28Gimv NV (ENXTBR:GIMB) and the management of Hemink Groep B.V. completed the acquisition of an unknown majority stake in Hemink Groep B.V. from management and Pontex Investment Partners.Gimv NV (ENXTBR:GIMB) and the management of Hemink Groep B.V. agreed to acquire an unknown majority stake in Hemink Groep B.V. from management and Pontex Investment Partners on July 22, 2025. A cash consideration will be paid by Gimv NV and the management. The management will retain a minority stake in the new structure. Hemink's current management team will co-invest, underlining their long-term commitment to the company's further growth. As part of the acquisition, Hemink will continue to operate under its own identity, with the same people, the same approach and the same ambition. The transaction is subject to customary conditions, including regulatory approvals and approval by the competition authorities. The transaction is expected to close in 2025. Oaklins’ team in the Netherlands acted as the exclusive debt advisor to Gimv. Anke van Holthe tot Echten, Freek Hilberdink, Klaas Wiersma, Louis Lutz and Gianluca Kreuze of Loyens & Loeff acted as legal advisor for Gimv NV. Oaklins N.V. acted as debt advisor to Gimv NV. Bas Stoetzer and Geert Damman of Oaklins’ team in the Netherlands acted as the exclusive debt advisor to Gimv. Gimv NV (ENXTBR:GIMB) and the management of Hemink Groep B.V. completed the acquisition of an unknown majority stake in Hemink Groep B.V. from management and Pontex Investment Partners in July, 2025.
お知らせ • Jul 23Gimv NV (ENXTBR:GIMB) and the management of Hemink Groep B.V. agreed to acquire an unknown majority stake in Hemink Groep B.V. from its former management and Pontex Investment Partners.Gimv NV (ENXTBR:GIMB) and the management of Hemink Groep B.V. agreed to acquire an unknown majority stake in Hemink Groep B.V. from its former management and Pontex Investment Partners on July 22, 2025. A cash consideration will be paid by Gimv NV and the management. The management will retain a minority stake in the new structure. Hemink's current management team will co-invest, underlining their long-term commitment to the company's further growth. As part of the acquisition, Hemink will continue to operate under its own identity, with the same people, the same approach and the same ambition. The transaction is subject to customary conditions, including regulatory approvals and approval by the competition authorities. The transaction is expected to close in 2025. Anke van Holthe tot Echten, Freek Hilberdink, Klaas Wiersma, Louis Lutz and Gianluca Kreuze of Loyens & Loeff acted as legal advisor for Gimv NV.
Declared Dividend • Jun 27Dividend of €1.82 announcedShareholders will receive a dividend of €1.82. Ex-date: 30th June 2025 Payment date: 25th July 2025 Dividend yield will be 4.1%, which is higher than the industry average of 2.6%. Sustainability & Growth Dividend is covered by earnings (35% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. Earnings per share has grown by 29% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
お知らせ • Jun 25Gimv NV and the management of Alpine Nederland B.V. acquired an unknown majority stake in Alpine Nederland B.V. from Vendis Capital, founders and management of Alpine Nederland B.V.Gimv NV and the management of Alpine Nederland B.V. agreed to acquire an unknown majority stake in Alpine Nederland B.V. from Vendis Capital, founders and management of Alpine Nederland B.V. on June 24, 2025. The management team reinvests part of its proceeds. A cash consideration will be paid by Gimv NV and the management. As part of consideration, an undisclosed value is paid towards common equity of Alpine Nederland B.V. The transaction remains subject to the works council advisory procedure. Floris Pierik of Jones Day (Netherlands) acted as legal advisor to Gimv NV.
お知らせ • Jun 24Cobepa S.A. acquired an unknown majority stake in Itineris NV from Participatiemaatschappij Vlaanderen NV, Gimv Arkiv II a fund managed by Gimv NV (ENXTBR:GIMB), SmartFin Capital I a fund managed by SmartFin Capital NV and Federal Holding and Investment Company.Cobepa S.A. acquired an unknown majority stake in Itineris NV from Participatiemaatschappij Vlaanderen NV, Gimv Arkiv II a fund managed by Gimv NV (ENXTBR:GIMB), SmartFin Capital I a fund managed by SmartFin Capital NV and Federal Holding and Investment Company on June 23, 2025. The investment marks a strong vote of confidence in Itineris’ strategy to become the global category leader in advanced software solutions for the utilities sector. Daiwa Corporate Advisory Limited acted as financial advisor for Itineris NV. Allen Overy Shearman Sterling LLP acted as legal advisor for Itineris NV. Four & Five acted as legal advisor for Itineris NV. Cobepa S.A. completed the acquisition of an unknown majority stake in Itineris NV from Participatiemaatschappij Vlaanderen NV, Gimv Arkiv II a fund managed by Gimv NV (ENXTBR:GIMB), SmartFin Capital I a fund managed by SmartFin Capital NV and Federal Holding and Investment Company on June 23, 2025.
お知らせ • May 28Bugaboo International B.V. acquired an unknown minority stake in Joolz from Gimv NV (ENXTBR:GIMB).Bugaboo International B.V. acquired an unknown minority stake in Joolz from Gimv NV (ENXTBR:GIMB) on May 27, 2025. Both Joolz and Bugaboo have agreed to join forces to accelerate their international growth in the fragmented worldwide stroller market. Bugaboo International B.V. completed the acquisition of an unknown minority stake in Joolz from Gimv NV (ENXTBR:GIMB) on May 27, 2025.
Reported Earnings • May 23Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: €57.2m (up 29% from 3Q 2024). Net income: €37.1m (up 26% from 3Q 2024). Profit margin: 65% (down from 67% in 3Q 2024). The decrease in margin was driven by higher expenses.
分析記事 • May 06Insufficient Growth At Gimv NV (EBR:GIMB) Hampers Share PriceWith a price-to-earnings (or "P/E") ratio of 7.2x Gimv NV ( EBR:GIMB ) may be sending bullish signals at the moment...
お知らせ • Mar 31Gimv NV to Report Fiscal Year 2025 Results on May 22, 2025Gimv NV announced that they will report fiscal year 2025 results on May 22, 2025
New Risk • Mar 12New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 28% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Shareholders have been diluted in the past year (28% increase in shares outstanding).
お知らせ • Feb 21Gimv NV agreed to acquired as unknown majority stake in The Spice Factory from Gilde Equity Management and Davy De Muyer.Gimv NV agreed to acquired as unknown majority stake in The Spice Factory from Gilde Equity Management and Davy De Muyer on February 20, 2025. Jorgen De Pelsmaeker, Chief Executive Officer, and the management team will reinvest alongside Gimv as the company embarks on its next phase of growth. Supported by the Gimv, The Spice Factory is expected to strengthen its market position and broaden its international reach. The transaction is expected to close before the end of March 2025.
お知らせ • Feb 04Gimv NV (ENXTBR:GIMB) acquired an unknown minority stake in Robojob NV.Gimv NV (ENXTBR:GIMB) acquired an unknown minority stake in Robojob NV on February 3, 2025. The aim of Gimv’s investment is to support RoboJob's international growth and enable the company to realise the full potential of the promising product offering. With this strong foundation complemented with the partnership that Gimv and the De Roovere family are now entering into, RoboJob is now in optimal shape to realise its growth ambitions. Gimv NV (ENXTBR:GIMB) completed the acquisition of an unknown minority stake in Robojob NV on February 3, 2025.
お知らせ • Dec 19B+N Referencia Zrt. agreed to acquire an unknown majority stake in Köberl Group from Gimv NV (ENXTBR:GIMB).B+N Referencia Zrt. agreed to acquire an unknown majority stake in Köberl Group from Gimv NV (ENXTBR:GIMB) on December 17, 2024. The deal is expected to close in the first quarter of 2025. Torsten Denker, Philipp Noack, Constantin vom Bauer, Olja Schmitt and Dominik Detels of IMAP Belgium acted as financial advisors for Gimv NV.
お知らせ • Dec 06Gimv NV, Eric Merilhou, Yann Dauce and the management of Tibbloc acquired an unknown majority stake in Tibbloc from Ciclad, SAS.Gimv NV, Eric Merilhou, Yann Dauce and the management of Tibbloc acquired an unknown majority stake in Tibbloc from Ciclad, SAS on December 4, 2024. A cash consideration will be paid by Gimv NV and the management. As part of consideration, an undisclosed value is paid towards common equity of Tibbloc. For the period ending December 31, 2023, Tibbloc reported total revenue of €40 million. Gimv NV, Eric Merilhou, Yann Dauce and the management of Tibbloc completed the acqusition of an unknown majority stake in Tibbloc from Ciclad, SAS on December 4, 2024.
お知らせ • Dec 04Gimv NV (ENXTBR:GIMB) and Wolf D. Koch agreed to acquire an unknown majority stake in Lupine Lighting Systems GmbH from Wolf D. Koch.Gimv NV (ENXTBR:GIMB) and Wolf D. Koch agreed to acquire an unknown majority stake in Lupine Lighting Systems GmbH from Wolf D. Koch on December 2, 2024. Wolf D. Koch, founder and chief executive officer, reinvesting part of his proceeds to hold a minority stake in the company. Financial details of the transaction remain undisclosed, pending successful closure.
分析記事 • Nov 27Benign Growth For Gimv NV (EBR:GIMB) Underpins Its Share PriceWhen close to half the companies in Belgium have price-to-earnings ratios (or "P/E's") above 14x, you may consider Gimv...
Reported Earnings • Nov 26First half 2025 earnings released: EPS: €5.15 (vs €5.81 in 1H 2024)First half 2025 results: EPS: €5.15 (down from €5.81 in 1H 2024). Revenue: €187.3m (down 7.9% from 1H 2024). Net income: €144.9m (down 8.4% from 1H 2024). Profit margin: 77% (in line with 1H 2024). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
お知らせ • Nov 22Fremman Limited agreed to acquire an unknown majority stake in rehaneo GmbH from Gimv NV (ENXTBR:GIMB).Fremman Limited agreed to acquire an unknown majority stake in rehaneo GmbH from Gimv NV (ENXTBR:GIMB) on November 20, 2024. The financing will be provided by Ares. Founder and chief executive officer Bruno Crone and co-founder and Chief operating officer Christoph Dühr remain significantly invested in the company and continue their management roles. The transaction is subject to approval by the German antitrust authorities and is expected to close in Q1 2025. Isabell Hitzer and Dr. Bernd Egbers of Astera Legal acted as legal advisor for Fremman Limited. Latham & Watkins acted as legal advisor to Ares.
お知らせ • Oct 16The Martens Brewery of Bocholt acquired United Dutch Breweries B.V. from Gimv NV (ENXTBR:GIMB) and management.The Martens Brewery of Bocholt acquired United Dutch Breweries B.V. from Gimv NV (ENXTBR:GIMB) and management on October 16, 2024. The Martens Brewery of Bocholt completed the acquisition of United Dutch Breweries B.V. from Gimv NV (ENXTBR:GIMB) and management on October 16, 2024.
お知らせ • Sep 06BiZZdesign BV agreed to acquire MEGA International S.A. from Gimv NV (ENXTBR:GIMB).BiZZdesign BV agreed to acquire MEGA International S.A. from Gimv NV (ENXTBR:GIMB) on September 4, 2024. The transaction is subject to approval by regulatory board / committee.
Upcoming Dividend • Jun 24Upcoming dividend of €1.82 per shareEligible shareholders must have bought the stock before 01 July 2024. Payment date: 26 July 2024. Payout ratio is a comfortable 33% but the company is not cash flow positive. Trailing yield: 5.7%. Lower than top quartile of Belgian dividend payers (7.2%). Higher than average of industry peers (3.0%).
New Risk • Jun 10New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Paying a dividend despite having no free cash flows. Shareholders have been diluted in the past year (2.4% increase in shares outstanding).
お知らせ • May 22WorxInvest NV completed the acquisition of 27.81% stake in Gimv NV (ENXTBR:GIMB) from Flemish Community.WorxInvest NV signed an agreement to acquire 27.81% stake in Gimv NV (ENXTBR:GIMB) from Flemish Community for approximately €370 million on November 30, 2023. The transaction is subject to customary regulatory approvals., Freshfields Bruckhaus Deringer LLP and Ernst & Young served as accountant to WorxInvest on the transaction. Rothschild & Co and Stibbe advised the Flemish Region on the transaction. Morgan Stanley acted as financial advisor to WorxInvest NV. Koen Vanhaerents, Guillaume Nataf, Frans Muller and Bram Hoorelbeke of Baker & Mckenzie acted as legal advisor to Gimv. As of April 15, 2024, The European Commission approved WorxInvest to buy Gimv.WorxInvest NV completed the acquisition of 27.81% stake in Gimv NV (ENXTBR:GIMB) from Flemish Community on May 21, 2024. All regulatory approvals obtained.
お知らせ • Feb 28Sagard SAS acquired Groupe Acceo from Gimv NV (ENXTBR:GIMB).Sagard SAS acquired Groupe Acceo from Gimv NV (ENXTBR:GIMB) on February 27, 2024. Moncey Avocats acted as legal advisor, Natixis Partners and UBS M & A Mid-Cap acted as financial advisor, KPMG Corporate Finance France, Indefi and Marsh & Mclennan Companies France acted as due diligence provider to Sagard SAS. Capitalmind Corporate Finance Advisory acted as financial advisor, Hogan Lovells (Paris) LLP acted as legal advisor, Oderis Consulting and EY-Parthenon acted as due diligence provider to Groupe Acceo shareholders. Sagard SAS completed the acquisition of Groupe Acceo from Gimv NV (ENXTBR:GIMB) on February 27, 2024.
お知らせ • Feb 03+ 2 more updatesGimv NV to Report Fiscal Year 2024 Results on May 23, 2024Gimv NV announced that they will report fiscal year 2024 results on May 23, 2024
Reported Earnings • Nov 26First half 2024 earnings released: EPS: €5.81 (vs €2.80 loss in 1H 2023)First half 2024 results: EPS: €5.81 (up from €2.80 loss in 1H 2023). Revenue: €203.3m (up 86% from 1H 2023). Net income: €158.2m (up €233.2m from 1H 2023). Profit margin: 78% (up from net loss in 1H 2023). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.
お知らせ • Sep 19Crédit Mutuel Equity signed an agreement to acquire unknown majority stake in Groupe CLAIRE SAS from Gimv NV (ENXTBR:GIMB).Crédit Mutuel Equity signed an agreement to acquire unknown majority stake in Groupe CLAIRE SAS from Gimv NV (ENXTBR:GIMB) on September 18, 2023. Completion of the transaction remains subject to the recommendation of Groupe Claire's employee representative bodies, as well as the authorization of the French Competition Authority.
Reported Earnings • May 21Full year 2023 earnings released: €2.20 loss per share (vs €6.59 profit in FY 2022)Full year 2023 results: €2.20 loss per share (down from €6.59 profit in FY 2022). Net loss: €59.5m (down 134% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
Reported Earnings • Jan 11First half 2023 earnings released: €2.80 loss per share (vs €5.22 profit in 1H 2022)First half 2023 results: €2.80 loss per share (down from €5.22 profit in 1H 2022). Revenue: €109.3m (down 48% from 1H 2022). Net loss: €75.1m (down 155% from profit in 1H 2022). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
お知らせ • Dec 10Management of Biolam acquired an unknown minority stake in Biolam from Gimv NV (ENXTBR:GIMB).Management of Biolam acquired an unknown minority stake in Biolam from Gimv NV (ENXTBR:GIMB) on December 9, 2022. Gimv is selling its stake in Biolam to its founding team, backed by private equity investors. Management of Biolam completed the acquisition of an unknown minority stake in Biolam from Gimv NV (ENXTBR:GIMB) on December 9, 2022.
Buying Opportunity • Nov 21Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 18%. The fair value is estimated to be €54.34, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last 3 years. Earnings per share has grown by 47%.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Frank Verhaegen was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Buying Opportunity • Nov 01Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 17%. The fair value is estimated to be €54.62, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last 3 years. Earnings per share has grown by 47%.
お知らせ • Oct 26Gimv NV to Report Fiscal Year 2023 Results on May 17, 2023Gimv NV announced that they will report fiscal year 2023 results on May 17, 2023
お知らせ • Oct 19Gimv NV, Annual General Meeting, Jun 28, 2023Gimv NV, Annual General Meeting, Jun 28, 2023.
Buying Opportunity • Aug 02Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 6.0%. The fair value is estimated to be €64.89, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last 3 years. Earnings per share has grown by 47%.
Buying Opportunity • Jun 22Now 20% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be €65.65, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last 3 years. Earnings per share has grown by 47%.
お知らせ • Jun 10GIMV NV (ENXTBR:GIMB) acquired 30% stake in Picot SA.GIMV NV (ENXTBR:GIMB) acquired 30% stake in Picot SA on June 9, 2022. Picot SA's shareholders and management will join GIMV NV. At the end of 2021, Picot had a turnover of €212 million. GIMV NV (ENXTBR:GIMB) completed the acquisition of 30% stake in Picot SA on June 9, 2022.
お知らせ • May 13GIMV NV (ENXTBR:GIMB) completed the acquisition of 20.87% stake in Bioconnection B.V. from Pharming Group N.V. (ENXTAM:PHARM).GIMV NV (ENXTBR:GIMB) reached an agreement to acquire 20.87% stake in Bioconnection B.V. from Pharming Group N.V. (ENXTAM:PHARM) for €6.9 million on April 22, 2022. Pharming will receive one-off €6.9 million net cash proceeds in Q2 2022. Pharming will continue to support BioConnection to accelerate its next stage of growth to further invest in its organization and infrastructure to increase the production capacity. GIMV NV (ENXTBR:GIMB) completed the acquisition of 20.87% stake in Bioconnection B.V. from Pharming Group N.V. (ENXTAM:PHARM) on May 12, 2022.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 2 highly experienced directors. Independent Director Frank Verhaegen was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Apr 23GIMV NV (ENXTBR:GIMB) reached an agreement to acquire 20.87% stake in Bioconnection B.V. from Pharming Group N.V. (ENXTAM:PHARM) for ?6.9 million.GIMV NV (ENXTBR:GIMB) reached an agreement to acquire 20.87% stake in Bioconnection B.V. from Pharming Group N.V. (ENXTAM:PHARM) for ?6.9 million on April 22, 2022. Pharming will receive one-off ?6.9 million net cash proceeds in Q2 2022. Pharming will continue to support BioConnection to accelerate its next stage of growth to further invest in its organization and infrastructure to increase the production capacity.
お知らせ • Apr 01STRACO acquired an unknown majority stake in Incendin NV from GIMV NV (ENXTBR:GIMB).STRACO acquired an unknown majority stake in Incendin NV from GIMV NV (ENXTBR:GIMB) on March 30, 2022. STRACO completed the acquisition of an unknown majority stake in Incendin NV from GIMV NV (ENXTBR:GIMB) on March 30, 2022.
Buying Opportunity • Feb 22Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 2.8%. The fair value is estimated to be €65.82, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% per annum over the last 3 years. The company has become profitable over the last year.
Price Target Changed • Dec 06Price target increased to €56.75Up from €53.00, the current price target is provided by 1 analyst. New target price is 5.9% above last closing price of €53.60. Stock is up 8.1% over the past year. The company posted earnings per share of €7.96 last year.
Reported Earnings • Nov 21First half 2022 earnings released: EPS €5.22 (vs €3.61 in 1H 2021)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2022 results: Revenue: €208.5m (up 21% from 1H 2021). Net income: €137.0m (up 46% from 1H 2021). Profit margin: 66% (up from 55% in 1H 2021). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
Reported Earnings • May 22Full year 2021 earnings released: EPS €7.96 (vs €5.96 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: €331.9m (up 125% from FY 2020). Net income: €205.7m (up €357.3m from FY 2020). Profit margin: 62% (up from net loss in FY 2020). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.
お知らせ • May 01GIMV NV (ENXTBR:GIMB) agreed to acquire an unknown minority stake in Projective NV.GIMV NV (ENXTBR:GIMB) agreed to acquire an unknown minority stake in Projective NV on April 29, 2021. The current partners and shareholders of the Projective Group will remain on board and retain the majority of the shares. For the year ended 2020, Projective reported a revenue of €45 million. The transaction is subject to customary closing conditions. Klaas Thibaut, Wout Hooyberghs and Cody Demuytere of Quinz acted as legal advisor for GIMV NV.
お知らせ • Mar 19+ 1 more updateGIMV NV (ENXTBR:GIMB) along with the management agreed to acquire an unknown majority stake in Verkley B.V. from PMH Investments.GIMV NV (ENXTBR:GIMB) along with the management agreed to acquire an unknown majority stake in Verkley B.V. from PMH Investments on March 17, 2021. In 2020, Verkley B.V. reported a total revenues of €38 million out of two facilitates one in Drachten (head office) and one in Groningen. The transaction is subject to customary closing conditions, including approval by the competition authorities.
Is New 90 Day High Low • Feb 26New 90-day low: €48.50The company is down 3.0% from its price of €49.75 on 27 November 2020. The Belgian market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Capital Markets industry, which is up 2.0% over the same period.
分析記事 • Feb 08How Does GIMV NV (EBR:GIMB) Fare As A Dividend Stock?Is GIMV NV ( EBR:GIMB ) a good dividend stock? How can we tell? Dividend paying companies with growing earnings can be...
Is New 90 Day High Low • Feb 03New 90-day high: €51.20The company is up 10.0% from its price of €46.35 on 04 November 2020. The Belgian market is up 16% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Capital Markets industry, which is up 9.0% over the same period.
お知らせ • Jan 20Belden Inc. (NYSE:BDC) entered into a definitive agreement to acquire OTN Systems N.V. from GIMV NV (ENXTBR:GIMB), Manuardeo and management for approximately $71 million.Belden Inc. (NYSE:BDC) entered into a definitive agreement to acquire OTN Systems N.V. from GIMV NV (ENXTBR:GIMB), Manuardeo and management for approximately $71 million on January 19, 2021. The transaction will be financed with cash on hand, which was approximately $500 million at the end of 2020. The transaction is subject to customary closing conditions and is expected to close in the first quarter 2021. The transaction has a positive impact of about $18.2 million (€15 million) on Gimv's net asset value as per September 30, 2020. The return over the entire investment period exceeds Gimv's long-term average.
Is New 90 Day High Low • Dec 28New 90-day high: €50.70The company is up 5.0% from its price of €48.20 on 29 September 2020. The Belgian market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Capital Markets industry, which is up 13% over the same period.
分析記事 • Dec 18Would Shareholders Who Purchased GIMV's (EBR:GIMB) Stock Year Be Happy With The Share price Today?Most people feel a little frustrated if a stock they own goes down in price. But sometimes a share price fall can have...
お知らせ • Dec 03Parcom Capital has reached an agreement to acquire majority stake in CFL Holding BV from GIMV NV (ENXTBR:GIMB).Parcom Capital has reached an agreement to acquire majority stake in CFL Holding BV from GIMV NV (ENXTBR:GIMB) on December 2, 2020. Bas Korte remains on board as group Chief Executive Officer. Parcom will support management with their continued value creation by focusing on the large opportunity in the energy transition of the residential building market. The transaction is subject to customary closing condition, including approval by regulatory authorities and competition authorities. Acquisition is expected to close early 2021. Transaction which represents the exit of the largest shareholding on Gimv's balance sheet, has a positive impact of about €20 million on Gimv's net asset value as per September 30, 2020.
Reported Earnings • Nov 22First half 2021 earnings released: EPS €3.61The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: €172.5m (up 12% from 1H 2020). Net income: €94.0m (up 83% from 1H 2020). Profit margin: 55% (up from 33% in 1H 2020). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 81% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
お知らせ • Nov 20+ 1 more updateGIMV NV, Annual General Meeting, Jun 30, 2021GIMV NV, Annual General Meeting, Jun 30, 2021.
Is New 90 Day High Low • Nov 19New 90-day high: €48.90The company is up 7.0% from its price of €45.60 on 21 August 2020. The Belgian market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Capital Markets industry, which is up 6.0% over the same period.
Is New 90 Day High Low • Oct 21New 90-day low: €45.45The company is down 4.0% from its price of €47.15 on 23 July 2020. The Belgian market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Capital Markets industry, which is down 1.0% over the same period.
お知らせ • Sep 30+ 1 more updateManagement of Ecu-Line and Allcargo acquired 100% stake in Ecu-Line from ABN AMRO and GIMV.Management of Ecu-Line and Allcargo acquired 100% stake in Ecu-Line from ABN AMRO and GIMV on June 16, 2005. The terms were not disclosed. For the year ended on December 31, 2004, Ecu-Line had consolidated sales of more than €180 million. Raymond Van Achteren, Marc Van Looveren and Kris De Witte (the management of Ecu-Line) has acquired majority stake and Allcargo acquired the minority stake. Deloitte Corporate Finance Belgium served as financial advisor and Laga & Philippe served as legal advisor to the management. Management of Ecu-Line and Allcargo completed the acquisition of 100% stake in Ecu-Line from ABN AMRO and GIMV on June 16, 2005.
お知らせ • Sep 25+ 2 more updatesKatoen Natie acquired Nieuwe Havema N.V. from GIMV, Mercator and other shareholders.Nieuwe Havema N.V. was acquired by Katoen Natie on September 16, 2003. GIMV and Mercator sold their stakes in Nieuwe Havema through the transaction. Sequoia Consulting BVBA acted as financial advisor to Werf en Vlasnatie N.V. Katoen Natie completed the acquisition of Nieuwe Havema N.V. on September 16, 2003.
お知らせ • Sep 23Individuals announced the acquisition of 40% stake in Begro N.V. from GIMV NV.GIMV NV (ENXTBR: GIMB) announced that it has agreed to sell it 40% stake in Begro N.V. to the individuals in 2001.
お知らせ • Aug 28An undisclosed buyer acquired an unknown stake in Govecs AG from GIMV NV (ENXTBR:GIMB).An undisclosed buyer acquired an unknown stake in Govecs AG from GIMV NV (ENXTBR:GIMB) in 2014. An undisclosed buyer completed the acquisition of an unknown stake in Govecs AG from GIMV NV (ENXTBR:GIMB) in 2014.
お知らせ • Aug 27The management of PROXIAD Group S.A.S. acquired an unknown stake in PROXIAD Group S.A.S. from GIMV NV (ENXTBR:GIMB).The management of PROXIAD Group S.A.S. acquired an unknown stake in PROXIAD Group S.A.S. from GIMV NV (ENXTBR:GIMB) in April 2015. The management of PROXIAD Group S.A.S. completed the acquisition of an unknown stake in PROXIAD Group S.A.S. from GIMV NV (ENXTBR:GIMB) in April 2015.
お知らせ • Aug 21Babyshop Sthlm AB acquired BEBEO SA from GIMV NV (ENXTBR:GIMB) and Nathalie Genty.Babyshop Sthlm AB acquired BEBEO SA from GIMV NV (ENXTBR:GIMB) and Nathalie Genty on August 20, 2020. GIMV and Nathalie Genty will join as shareholders of Melijoe. Melijoe will continue to trade separately and benefit from the capabilities of the group. Melijoe had revenue in excess of €20 million. GIMV and Nathalie Genty will stay on board. Carnegie Investment Bank acted as sole financial advisor for Babyshop Sthlm AB. Babyshop Sthlm AB completed the acquisition of BEBEO SA from GIMV NV (ENXTBR:GIMB) and Nathalie Genty on August 20, 2020.
お知らせ • Jul 01Tosca Services, LLC agreed to acquire Contraload NV from founders(Sylvain Naets and Jesse Sels) along with Down2Earth fund managed by Down 2 Earth Capital NV and GIMV NV (ENXTBR:GIMB).Tosca Services, LLC agreed to acquire Contraload NV from founders (Sylvain Naets and Jesse Sels) along with Down2Earth fund managed by Down 2 Earth Capital NV and GIMV NV (ENXTBR:GIMB) on June 29, 2020. In conjunction with the transaction, funds advised by Apax Partner, which acquired Tosca in 2017, will commit additional capital to Tosca to fund the acquisition of Contraload NV. Contraload reported sales of €46 million for the year 2019. Contraload's team will join Tosca Services group through this transaction. Ben Schaye, Ryerson Symons, Jonathan Goldstein, Adam D. Shapiro, Sara Y. Razi, David E. Vann, Derek Baird, Ellen L. Frye, Patricia K. Adams, Lori E. Lesser, Genevieve Dorment, Steven R. DeLott, Michael R. Isby of Simpson Thacher & Bartlett LLP acted as legal advisors to Tosca Services, LLC and Apax Partners LLP.